BTG narrows focus to pharmaceuticals & medical technologies
This article was originally published in Clinica
Declining revenues and rising losses at UK technology developer BTG has led CEO Louise Makin to narrow the company's remit. It will no longer seek new opportunities in the physical sciences sector but will focus on pharmaceuticals and other medical technologies, said Ms Makin, who was appointed in October 2004.
You may also be interested in...
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.
Rosa DeLauro prevails over fellow Democrats Debbie Wasserman Schultz and Marcy Kaptur for Appropriations chair. Frank Pallone gets unanimous support from Democrats to continue as Energy and Commerce chair.